Skip to content
Breathing, swallowing or vision problems: call the emergency services (15 or 112 in France).

Botox chin: the "orange peel" chin, why and how?

A chin that puckers into an "orange peel" texture is linked to an overactive muscle, the mentalis. Botulinum toxin can relax it temporarily. This use is described by expert consensus documents, but it is not in any French product label: it is off-label. Here is what is known, and what to ask your doctor.

The chin is one of the eleven areas of our atlas of botulinum toxin by area of the face. This page explains where the "orange peel" chin comes from, what the toxin can and cannot do, why it is an off-label use in France, and what its risks are. It does not replace a consultation.

Why is the chin treated?

The mentalis is a small paired muscle that arises from the bone of the lower jaw1 and attaches to the skin of the chin. When it contracts, it puckers the skin of the chin. If it is very active, the skin takes on a dimpled appearance, like "orange peel" or a "golf ball"1,2.

Botulinum toxin temporarily relaxes this muscle, which smooths the chin in motion. It is the main muscle targeted to treat this appearance1. An Italian expert consensus published in 2026 identifies the orange peel appearance and overactivity of the mentalis as the indications with the strongest agreement2. The "dimpled chin" also appears in the 2004 and 2010 consensus documents3,4. The 2010 one was written by an expert board convened around one manufacturer’s product4.

What the toxin does not do: it does not change the shape or bony projection of the chin, and it does not correct sagging skin in the lower face. Downturned mouth corners depend on another muscle, the depressor anguli oris, which the same consensus addresses separately2.

When is the toxin used?

There are no official criteria, since no French label provides for this area. The expert consensus documents concern an overactive mentalis and the resulting orange peel appearance2. They stress individual assessment of each patient3, and the 2026 consensus highlights the value of ultrasound to identify each person’s anatomical variations2.

The contraindications in the labels apply whatever the area: allergy to the toxin or to a component of the product, a generalised disorder of the muscles and of the junction between nerve and muscle (myasthenia gravis, Lambert-Eaton syndrome), an infection at the injection site5,6. Treatment is not recommended during pregnancy or breastfeeding5,6.

Which toxin for the chin?

Approval status in France: Chin
ToxinStatus in France
Long-acting botulinum toxin (type A)No aesthetic indication for this area in the SmPCs in force in France: off-label use, to be discussed with your doctor
Short-acting botulinum toxin (serotype E)No aesthetic indication for this area in the SmPCs in force in France: off-label use, to be discussed with your doctor

The type A toxins approved for aesthetic use in France cover frown lines and, depending on the product, crow’s feet and forehead lines6. None provides for the chin. The short-acting botulinum toxin (serotype E) is approved for frown lines only, in the European Union and in Canada5,7. For this area, any injection is therefore off-label. The consensus documents cited concern type A toxins2,3,4.

Status as of 9 October 2026: no French label provides for treatment of the chin5,6. It is an off-label use, described by expert consensus, which should be presented to you as such2.

Is it right for me?

Your doctor will look at your chin at rest and when you close your mouth, the position of your lips and the shape of your jaw. A chin that tenses because the lips have trouble closing, for example because of the position of the teeth, may call for a dental or orthodontic opinion as much as an injection. They will take into account your medical history, your treatments and any pregnancy plans.

The neighbouring lip area is covered on the page about botulinum toxin around the mouth; the jaw on the page about the masseter, and the neck on the page about neck bands.

Questions to ask your doctor: is this treatment off-label? What result is reasonable? Could the way I speak, eat or smile change? How long does the effect last, in your experience?

Onset and duration

No label gives an onset or duration for the chin, and the abstracts of the consensus documents consulted provide no figure2,3,4. We therefore do not give one. For the approved areas, type A labels describe an improvement within a few days and an effect lasting up to about 4 months6.

How these timelines work in general is explained on the page about how long botulinum toxin takes to work.

What are the risks in this area?

A 2023 anatomical review cites two side effects of a poorly placed injection in the chin: incomplete closure of the mouth, and an uneven smile caused by drooping of the lower lip1. The 2026 consensus points out that the lower face is a delicate area, because its muscles have important functions, which increases the risk of side effects2. The injection-site reactions described in the labels (pain, swelling, small bruise) are also possible5. A muscle that is only partly relaxed can also leave the chin bumpy, through paradoxical bulging2: the page on a dimpled or bumpy chin after an injection explains what to do. These effects are temporary.

Difficulty swallowing, speaking or breathing requires immediate medical attention5. If your chin feels stiff or your smile seems different after an injection, the page on the chin after an injection describes the most common situations.

Key points

  • The "orange peel" chin comes from an overactive mentalis muscle1,2.
  • The treatment is described by expert consensus documents, but no French label provides for it2,3,6.
  • It is an off-label use, for every toxin5,6.
  • Main risks: incomplete closure of the mouth, an uneven smile, both temporary1.

Frequently asked questions

  • Why does the chin pucker into an "orange peel" texture?

    This dimpled appearance, sometimes compared to a golf ball, is linked to an overactive mentalis muscle1,2. This small paired muscle arises from the bone of the lower jaw1 and attaches to the skin of the chin; when it contracts, it puckers the skin. It is the chin indication with the strongest agreement among experts2.

  • Is treating the chin with botulinum toxin approved in France?

    No. The type A toxins approved for aesthetic use cover frown lines and, depending on the product, crow’s feet and the forehead6; the short-acting toxin covers frown lines only5. The chin is described in expert consensus documents2,3,4, but it is an off-label use, which should be presented to you as such.

  • What are the risks of an injection in the chin?

    An anatomical review cites two side effects linked to a poorly placed injection: incomplete closure of the mouth and an uneven smile, caused by drooping of the lower lip1. These effects are temporary. Good knowledge of chin anatomy helps to limit them1. Report any troublesome effect to the doctor who performed the injection.

Sources

  1. 1.Yi K.H. et al., anatomical landmarks for botulinum toxin injection into the mentalis muscle: a review, Anatomy & Cell Biology, 2023 (opens in a new tab) — Anatomy & Cell Biology
  2. 2.Fundarò S. et al., Italian consensus and review on treating the lower face muscles with type A botulinum toxin, Toxins, 2026 (opens in a new tab) — Toxins (MDPI)
  3. 3.Carruthers J. et al., expert consensus on botulinum toxin in facial aesthetics, Plastic and Reconstructive Surgery, 2004 (opens in a new tab) — Plastic and Reconstructive Surgery
  4. 4.Ascher B. et al., international consensus recommendations on type A botulinum toxin in aesthetics, part II: middle and lower face, neck and chest, Journal of the European Academy of Dermatology and Venereology, 2010 (expert board convened around one manufacturer’s product) (opens in a new tab) — Journal of the European Academy of Dermatology and Venereology
  5. 5.Summary of product characteristics of the serotype E botulinum toxin approved in the European Union (EPAR annex I) (opens in a new tab) — European Commission (Union Register of medicinal products)
  6. 6.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 68150775) (opens in a new tab) — French public medicines database (BDPM)
  7. 7.Canadian product monograph of the serotype E botulinum toxin (authorization date: 2026-06-22) (opens in a new tab) — Health Canada
Book an appointmentSOS after an injection